There are plenty of ASX shares for investors to choose from.
To narrow things down, let's see what analysts are saying about three popular shares, courtesy of The Bull. Here's what they are recommending:
Image source: Getty Images
BHP Group Ltd (ASX: BHP)
The team at Sanlam Private Wealth is positive on mining giant BHP and has named it as a buy this week.
It believes recent share market volatility has created an opportunity for investors to snap up the Big Australian's shares at an attractive price. It explains:
The current volatility presents investors with an opportunity to buy this global miner at attractive prices. The recent BHP announcement of Brandon Craig replacing the retiring Mike Henry as chief executive is a good appointment. Craig was responsible for the company's Americas business, and that's where the growth is likely to come from in the medium term. Group revenue in the first half of 2026 was up 11 per cent on the prior corresponding period and profit from operations was up 34 per cent.
Guzman Y Gomez Ltd (ASX: GYG)
Over at Catapult Wealth, its analysts aren't positive on this quick service restaurant operator. Despite its shares falling heavily from recent highs, they have named Guzman Y Gomez as a sell this week.
Catapult Wealth highlights that the company's shares are still trading on a high price to earnings ratio despite recent weakness. It feels there are better options out there for investors, saying:
GYG is a Mexican themed restaurant chain. Although network sales grew 18 per cent to $682 million in the first half of fiscal year 2026, several metrics signal caution. Segment underlying EBITDA in the United States posted a loss of $8.3 million. The stock continues to trade on high price/earnings multiples. In our view, execution risks are rising and margins are under pressure. Investors may find better opportunities by re-allocating funds to alternative investments. GYG shares have fallen from $31 on March 31, 2025 to trade at $16.81 on March 26, 2026.
Pro Medicus Ltd (ASX: PME)
One ASX share that Catapult Wealth is positive on is Pro Medicus. It has named the health imaging technology company as a buy.
Due to its strong long-term growth outlook, it believes Pro Medicus shares would be an attractive addition to a portfolio this week. It said:
Pro Medicus develops advanced medical imaging software used by major hospitals and radiology groups globally. The company reported a strong first half result in fiscal year 2026, with revenue up 28.4 per cent to $124.8 million and underlying profit before tax rising 29.7 per cent to $90.7 million. In March, PME secured two important contract renewals worth a minimum of $40 million, both at higher transaction fees, signalling strengthening pricing power. With an underlying earnings before interest and tax margin at 73 per cent and cash of $222 million, PME remains financially robust. Growing US market share supports a positive long term growth outlook, making PME an attractive portfolio addition.
